CN103285326A - Medicine composition for treating gastrointestinal motility disorder - Google Patents
Medicine composition for treating gastrointestinal motility disorder Download PDFInfo
- Publication number
- CN103285326A CN103285326A CN2013102265572A CN201310226557A CN103285326A CN 103285326 A CN103285326 A CN 103285326A CN 2013102265572 A CN2013102265572 A CN 2013102265572A CN 201310226557 A CN201310226557 A CN 201310226557A CN 103285326 A CN103285326 A CN 103285326A
- Authority
- CN
- China
- Prior art keywords
- gastrointestinal motility
- motility disorder
- stomach
- treatment
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine composition for treating gastrointestinal motility disorder. The composition is characterized by comprising the following raw medicines in parts by weight: 10-20 parts of zedoary, 7-15 parts of fructus amomi, 7-15 parts of betel nut, 7-15 parts of costus root and 7-15 parts of spikenard. According to the technical scheme, zedoary, fructus amomi, betel nut, costus root and spikenard are composited on the basis of theory of traditional Chinese medicine and through the adjustment of the lifting motion of spleen and stomach and the synergistic effect on the aspects of promoting qi circulation, resolving dampness, eliminating accumulation, stopping pain and the like, the purposes of promoting gastrointestinal motility and treating gastrointestinal motility disorder are achieved.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of pharmaceutical composition for the treatment of gastrointestinal motility disorder.
Background technology
Digestive tract power is the important component part of digestive tract physiological function, and its dysfunction then is one of deciding factor that causes symptom of digestive tract.The unusual digestive tract complication with multiple digestive system disease and other systemic disease of digestive tract power is closely related.Be the commonly encountered diseases of clinical Digestive System Department by the disease due to the gastrointestinal motility disorder, as being that the functional dyspepsia of cardinal symptom accounts for more than 1/3 of gastrointestinal special outpatient clinic patient with the gastrointestinal motility obstacle, life to the patient has tangible influence, if add gastritis, the kinetics abnormal diseases that organic diseases such as ulcer cause, then incidence rate is higher.Therefore carry out the research of digestive tract power medicine significance is arranged.But, still lacking very effective treatment means clinically, modern medicine also only starts from nearest 20 years to its understanding and research, still has many bases and clinical problem to be illustrated.In recent years along with to the going deep into of the research of digestive tract power, the extensive use clinically of medicine for stomach dynamic such as motilium, cisapride, but the western medicine curative effect is not good enough at present, and symptom has had a strong impact on patient's work, life repeatedly.Long-term clinical practice shows that Chinese medicine can be used for the treatment of gastrointestinal motility dysfunction symptom as above distention and fullness in the abdomen, stomachache, belch, poor appetite, constipation etc., good effect and few side effects effectively.
Summary of the invention
The invention provides a kind of pharmaceutical composition for the treatment of gastrointestinal motility disorder, its objective is by optimizing preparation prescription provides a kind of Chinese medicine preparation in stable curative effect aspect the treatment gastrointestinal motility disorder.
For achieving the above object, the technical solution used in the present invention is: a kind of pharmaceutical composition for the treatment of gastrointestinal motility disorder, formed by the crude drug of following parts by weight:
Rhizoma Curcumae 10-20 part;
Fructus Amomi 7-15 part;
Semen Arecae 7-15 part;
Radix Aucklandiae 7-15 part;
Radix Et Rhizoma Nardostachyos 7-15 part.
In the such scheme, the preferable amount ranges of each crude drug is in the described pharmaceutical composition:
Rhizoma Curcumae 12-18 part;
Fructus Amomi 8-12 part;
Semen Arecae 8-12 part;
Radix Aucklandiae 8-12 part;
Radix Et Rhizoma Nardostachyos 8-12 part.
Therapeutic mechanism of the present invention is: the traditional Chinese medical science is thought the etiology and pathogenesis of gastrointestinal motility disorder mostly by dysfunction of spleen and stomach, abnormal ascending-descending of QI, and middle burnt the heap soil or fertilizer over and around the roots stagnates, and the mechanism of qi retardance is due to the spleen-QI sinking, adverse rising of stomach-QI.Pharmaceutical composition of the present invention is from the main pathomechanism incision of gastrointestinal motility disorder, select for use the medicine of Rhizoma Curcumae, Fructus Amomi, Semen Arecae, the Radix Aucklandiae, Radix Et Rhizoma Nardostachyos five tastes circulation of qi promoting removing dampness sending down the abnormal ascending QI to constitute, wherein Rhizoma Curcumae is as principal agent, has the dispelling the stagnated QI long-pending effect that helps digestion, Fructus Amomi, Semen Arecae, the Radix Aucklandiae, Radix Et Rhizoma Nardostachyos are as accessory drugs, effect with removing dampness, circulation of qi promoting spleen invigorating, can strengthen the effect of consumer product dredge stasis, in addition, Radix Et Rhizoma Nardostachyos has also been strengthened the merit of the capable appetizing of loosing, be amusing of perfect square fragrance, clinical practice also proves better efficacy, and patient's reflection takes effect faster, and compliance is better; All medicines share, and have the effect of invigorating the spleen for eliminating dampness, regulating qi-flowing for activating stagnancy, and its mechanism of action organizes the expression of 5-HT3R relevant with increase digestive tract power and adjusting duodenum.That is to say, technical scheme of the present invention according to theory of Chinese medical science with Rhizoma Curcumae, Fructus Amomi, Semen Arecae, the Radix Aucklandiae, Radix Et Rhizoma Nardostachyos prescription, by the function of spleen and stomach regulating elevating movement and at the synergism of aspects such as circulation of qi promoting, removing dampness, removing food stagnancy, pain relieving, reach the purpose that promotes digestive tract power, treatment gastrointestinal motility disorder.
The pharmacology of each Chinese medicine ingredients and the property of medicine are as follows in the pharmaceutical composition of the present invention:
Rhizoma Curcumae: hot, bitter, temperature.Return liver, spleen channel.The removing food stagnancy eliminating stagnation, can circulation of qi promoting the removing food stagnancy pain relieving, be used for eating accumulation, the breast abdominal distention is vexed has a pain.There are some researches show that 25% Rhizoma Curcumae water decoction can obviously improve gastrointestinal electricity arhythmicity and rat stomach Emptying Rate.
Fructus Amomi: acrid in the mouth, warm in nature.Have that removing dampness is amusing, the effect of circulation of qi promoting warming middle-JIAO, Compendium of Material Medica record " tonifying the lung is amusing, nourishing the stomach kidney tonifying, reason vigour, dispelling stagnant Qi, dispelling cold fluid-retention and abdominal distension, dysphagic vomiting ".The modern pharmacology experiment shows that Fructus Amomi can increase motilin (MTL) level of blood plasma, gastric antrum and jejunum tissue homogenate.
Semen Arecae: property suffering, temperature, bitter in the mouth is nontoxic.Return the harmonization of the stomach large intestine channel, the function of parasite killing, consumer product dredge stasis, promoting the circulation of QI to induce diuresis is arranged.Can treat stagnation of QI due to dyspepsia, diseases such as stomachache distension constipation.How on the books the successive dynasties book on Chinese herbal medicine is, " Newly Revised Canon of Materia Medica ": " control abdominal distention, give birth to and smash end clothes, diuretic anus "." bright doctor does not record ": " rapid digestion of food dewaters, except accumulation of phlegm in the hypochondrium "." herbal explicit word ": " Semen Arecae go into the breast abdomen is broken to stagnate gas and do not stop "." medication heart method ": " Semen Arecae, bitter with broken stagnant, hot evil to loose, it is descending specially to break the gas that stagnates ".Research in recent years also shows that Semen Arecae has stronger short gastrointestinal motility effect.
The Radix Aucklandiae: return spleen, stomach, liver, lung meridian.Promoting the circulation of QI to relieve pain; Intestinal stasis relieving in the accent.The Radix Aucklandiae has the effect of circulation of qi promoting spleen invigorating, and it has and promotes gastric emptying and intestinal transmission effects, and serves as remarkable to strengthen gastric emptying.
Radix Et Rhizoma Nardostachyos: acrid in the mouth, sweet, warm in nature; Return spleen, stomach warp; The fragrance row looses.Radix Et Rhizoma Nardostachyos has warming spleen and stomach for dispelling cold, regulating QI to relieve pain, the effect of the appetizing of being amusing; Radix Et Rhizoma Nardostachyos cures mainly the coldness and pain in the epigastrium distension, anorexia, chest pain, toothache, the tumbling down pain of injury, beriberi edema, cramp caused by acute vomiting and diarrhea.Compendium of Material Medica: " Radix Et Rhizoma Nardostachyos, it is strongly fragrant that fragrance can be opened spleen, adds in the taste medicine gas of very being amusing less "." book on Chinese herbal medicine converges and says ": " Radix Et Rhizoma Nardostachyos, the medicine of the smooth stomach of being amusing also." " opening treasured side " " main sudden attack of pain in the chest and abdomen, the full therapeutic method to keep the adverse QI flowing downwards of loosing is all got the diffusing meaning of Wen Xianghang.Its gas fragrance is gone in the taste medicine, holds up spleen pleasant greatly, the merit of appetite-stimulating indigestion-relieving." " Japan hanako materia medica ": " control abdominal distnetion, the therapeutic method to keep the adverse QI flowing downwards." Radix Et Rhizoma Nardostachyos is to the effect of smooth muscle: giving the forward and backward of Cavia porcellus jet tissue amine, using jatamansi and can make bronchiectasis.Alcohol extract is (small intestinal, large intestine, uterus, bronchus) on the isolated smooth muscle organ, has the effect of antagonism histamine, 5-hydroxy tryptamine and acetylcholine; The spasm that can also the antagonism barium chloride causes is so still have direct effect to smooth muscle.Clinically with control asthma, cough, drop, stomachache etc. may be relevant therewith.
The main pharmacodynamics data of pharmaceutical composition of the present invention:
1, pharmaceutical composition of the present invention influence that gastrointestinal motility disorder rat small intestine due to the Radix Glycyrrhizae is advanced
Adopt the Radix Glycyrrhizae administration by gavage to set up the gastrointestinal motility disorder rat model, the 2nd day from model foundation begins rats gavaged medicine of the present invention (claiming stomach moving side again), continue to irritate in 3 days the moving side of stomach and the not husky Billy (1.4mg/kg) of stomach heavy dose (10.8g/kg), middle dosage (3.6g/kg), low dose of (1.2g/kg), estimate the moving side of stomach to the therapeutical effect of gastrointestinal motility disorder rat model by the detection of intestinal propulsion ratio.The result shows: the large, medium and small dosage group rat small intestine impelling ratio in the moving side of stomach all has raising in various degree, wherein the stomach heavy dose of group in moving side and middle dosage group are compared with model group and are had significant difference, the difference of comparing with the blank group is little, illustrate that there is certain therapeutical effect the moving side of stomach to the intestinal motility dysfunction, though but the moving square small dose group rat small intestine impelling ratio of stomach has raising, relatively do not have significant difference with model group, the moving side of low dose of stomach is not obvious to the improvement effect of intestinal motility obstacle.Generally speaking, the moving intestinal propulsion function that can enough promote gastrointestinal motility disorder rat model due to the Radix Glycyrrhizae of stomach.
2, pharmaceutical composition of the present invention is to the influence of gastrointestinal motility disorder rat model gut hormone content
At pharmaceutical composition of the present invention to influencing on the experiment basis that gastrointestinal motility disorder rat small intestine due to the Radix Glycyrrhizae advances, adopt the method that gut hormone detects in the blood, observe the situation of change of gastrin (GAS), motilin (MTL) and vasoactive peptide (VIP) content, the result shows: model group MT in serum L content obviously reduces, and GAS and VIP content obviously raise; The MTL content of the big or middle dosage group in the moving side of stomach obviously raises, and reaches that relatively there were significant differences with model group, and GAS and VIP level reduce degree and model group more also there were significant differences.Though above-mentioned intestinal hormone level has optimum improvement trend in the moving side of low dose of stomach group, does not reach significance with the model group difference.Illustrate that gastrointestinal motility disorder due to the Radix Glycyrrhizae rat model and MTL, GAS and the disorder of VIP secretion level have certain relation, it may be the reason of gastrointestinal motility disorder that the reduction of MT in serum L content, GAS and VIP content increase; The moving side of stomach has the optimum improvement effect of gut hormone, and it is to the facilitation of digestive tract power, and the inherence that may exist gut hormone to change is basic.Therefore, the moving variation that can enough regulate gastrointestinal motility disorder rat model blood GAS, MTL, VIP hormone-content of stomach.
3, pharmaceutical composition of the present invention is to the influence of gastrointestinal motility disorder rat preduodenal 5-hydroxy tryptamine (5-HT) content
At pharmaceutical composition of the present invention to influencing on the experiment basis that gastrointestinal motility disorder rat small intestine due to the Radix Glycyrrhizae advances, adopt the method for SABC to observe the changes of contents situation of 5-HT in each group rat preduodenal tissue, immunohistochemical staining shows: the EC cell quantity of model group rat preduodenal tissue secretion 5-HT obviously increases, be higher than normal control group (P＜0.05), after treatment, each dosage group of the moving side of stomach and not husky Billy organize rat preduodenal and organize 5-HT content to return to normal level (P〉0.05) substantially; Difference not obvious (P〉0.05) between each group of staining power.This experimental result, gastrointestinal motility disorder rat model duodenum organizes the normal rat of 5-HT that the trend that increases is arranged, and after stomach moving side treatment, organize the 5-HT level can recover near normal level, consistent with not husky Billy's therapeutical effect, the disorder of hints model rat tissue 5-HT level, and the moving content that can regulate 5-HT disorderly in the gastrointestinal motility disorder rat model duodenum tissue of stomach, make it to return to normal level, in conjunction with reported in literature, illustrate that also the moving side of stomach may have dual regulation to 5-HT.
4, pharmaceutical composition of the present invention is to the influence of gastrointestinal motility disorder rat preduodenal 5-HT3aR mRNA expression
At pharmaceutical composition of the present invention to influencing on the experiment basis that gastrointestinal motility disorder rat small intestine due to the Radix Glycyrrhizae advances, use real-time fluorescence quantitative PCR (Real-Time PCR) technology, research 5-HT3aR mRNA is at the in-house expression of gastrointestinal motility disorder rat preduodenal, the result shows: compare with the blank group, the model group rat preduodenal organizes the expression of 5-HT3R to increase, its content is 1.8 times of blank group, after the moving side of process stomach and not husky Billy treated 3 days, stomach was moving square big, in, small dose group and Mo Sha Billy organize rat preduodenal and organize the expression of 5-HT3R that in various degree reduction is all arranged.Therefore, stomach is moving can enough regulate the expression that duodenum is organized 5-HT3R.
The specific embodiment
Be further described below in conjunction with the present invention of embodiment:
Embodiment one: a kind of pharmaceutical composition for the treatment of gastrointestinal motility disorder
The pharmaceutical composition prescription is made up of the crude drug of following parts by weight:
Rhizoma Curcumae 15g;
Fructus Amomi 10g;
Semen Arecae 10 g;
The Radix Aucklandiae 10 g;
Radix Et Rhizoma Nardostachyos 10 g.
Embodiment two: a kind of pharmaceutical composition for the treatment of gastrointestinal motility disorder
The pharmaceutical composition prescription is made up of the crude drug of following parts by weight:
Rhizoma Curcumae 10 g;
Fructus Amomi 7 g;
Semen Arecae 7 g;
The Radix Aucklandiae 7 g;
Radix Et Rhizoma Nardostachyos 7 g.
Embodiment three: a kind of pharmaceutical composition for the treatment of gastrointestinal motility disorder
The pharmaceutical composition prescription is made up of the crude drug of following parts by weight:
Rhizoma Curcumae 12 g;
Fructus Amomi 8 g;
Semen Arecae 8 g;
The Radix Aucklandiae 8 g;
Radix Et Rhizoma Nardostachyos 8 g.
Embodiment four: a kind of pharmaceutical composition for the treatment of gastrointestinal motility disorder
The pharmaceutical composition prescription is made up of the crude drug of following parts by weight:
Rhizoma Curcumae 20 g;
Fructus Amomi 15 g;
Semen Arecae 15 g;
The Radix Aucklandiae 15 g;
Radix Et Rhizoma Nardostachyos 15 g.
Embodiment five: a kind of pharmaceutical composition for the treatment of gastrointestinal motility disorder
The pharmaceutical composition prescription is made up of the crude drug of following parts by weight:
Rhizoma Curcumae 18 g;
Fructus Amomi 12 g;
Semen Arecae 12 g;
The Radix Aucklandiae 12 g;
Radix Et Rhizoma Nardostachyos 12 g.
Embodiment six: a kind of pharmaceutical composition for the treatment of gastrointestinal motility disorder
The pharmaceutical composition prescription is made up of the crude drug of following parts by weight:
Rhizoma Curcumae 16 g;
Fructus Amomi 11 g;
Semen Arecae 11 g;
The Radix Aucklandiae 11 g;
Radix Et Rhizoma Nardostachyos 9 g.
Functional dyspepsia is the commonly encountered diseases of digestive system, and clinical manifestation is that upper abdomen is glutted, full, burn feeling early, belch, nausea and vomiting and inenarrable epigastric discomfort sense etc., and its morbidity is relevant with gastrointestinal motility disorder.The western medicine curative effect is not good enough at present, and symptom has had a strong impact on patient's work, life repeatedly.The applicant adopts pharmaceutical composition prescription of the present invention (claiming stomach moving side again) treatment functional dyspepsia, the clinical curative effect that has obtained satisfaction.
Clinical practice example: after Chinese medicinal granule (being provided by the Jiangsu Tian Jiang Pharma Inc.) mixing with each component of the present invention, be washed into suspension with 150 ~ 200ml eliminating cold for resuscitation water, oral, treatment patients with functional dyspepsia 29 examples, and with 31 examples of taking not husky Billy treatment in contrast, by symptom before and after the treatment serum motilin is when measured, it is remarkable to obtain the moving side's treatment of stomach patients with functional dyspepsia clinical efficacy, now is reported as follows:
1 data and method
1.1 clinical data: this is organized 60 routine patients and derives from my outpatient service of Gastroenterology dept. of institute and ward of in June, the 2012 ~ 2012 year l2 month, is divided into two groups at random, and male l0 example is organized in treatment, women 19 examples, age 26-64 year, 37 years old mean age; Matched group man 12 examples, women 19 examples, age 24-63 year, 37.5 years old mean age.All patients all do gastroscope, B ultrasonic, blood, urine, stool routine and biochemical a complete set of the inspection.
1.2 go into the group standard: all patients meet following 4 conditions: (1) all have epigastrium pain, early full, abdominal distention, belch, feel sick, indigestion symptom such as acid regurgitation; (2) endoscopy is not found organic diseases such as peptic ulcer, reflux esophagitis, tumor in upper digestive tract; (3) laboratory, B ultrasonic, the biochemical a complete set of pathological changes of getting rid of influence digestion such as liver and gall spleen pancreas; (4) no abdominal operation history.The sequencing of going to a doctor by patient is divided into treatment group and matched group at random.
1.3 Therapeutic Method: the moving side for the treatment of group oral Chinese medicine stomach (Rhizoma Curcumae 15 grams, Fructus Amomi 10 grams, the living Radix Aucklandiae 10 grams, Semen Arecae 10 grams, Radix Et Rhizoma Nardostachyos 10 grams provide Chinese medicinal granule by Jiangsu Tian Jiang Pharma Inc.); 5mg of the oral mosapride citrate of matched group (the auspicious fine jade of trade name, Haosen Pharmaceutical Co., Ltd., Lianyungang produces), every day three times.Be for 4 weeks the course for the treatment of.And respectively at the clearing stomach therbligs level of having a blood test of drawing blood before and after the treatment.
1.4 efficacy assessment standard
The symptom evaluation criteria: asymptomatic is 0 minute; After prompting, can recognize that symptom exists for 1 fen; Symptom exists but do not influence daily life is 2 minutes; It is 3 minutes that symptom influences daily life.
Efficacy evaluation: produce effects, integration reduces more than 80%; Effectively, integration reduces by 50～80%; Invalid, integration reduces below 50%.
1.5 statistical method adopts 18.0 editions softwares of SPSS to carry out statistical analysis, two groups of clinical efficacies are used X
2Check, P＜0.05 expression difference has statistical significance.
2 results
2.1 after treating for 4 weeks, treatment group curative effect sees Table shown in the l apparently higher than matched group (P＜0.05).Treatment group serum motilin level is shown in Table 2 apparently higher than matched group (P＜0.05).
The two groups of patients with functional dyspepsia symptoms in table 1 treatment 4 week back relatively
| Group | The example number | Produce effects example number | Obvious effective rate (%) | Total effective routine number (%) | Total effective rate (%) |
| The treatment group | 29 | 25 | 86.2* | 27 | 93.1** |
| Matched group | 31 | 21 | 67.7 | 25 | 80.6 |
Explanation for table 1 partial content: (1) total effective rate=cure rate+obvious effective rate+effective percentage; (2) * P＜0.05, * * P＜0.05.
As can be seen from Table 1, the obvious effective rate for the treatment of group and total effective rate all are higher than matched group, and have significance (P＜0.05), i.e. treatment group curative effect is apparently higher than matched group.
The two groups of patients with functional dyspepsia serum motilins in table 2 treatment 4 week back relatively
| Group | The example number | Before the treatment (ng/L) | Treatment back (ng/L) |
| The treatment group | 29 | 196.00±26.25 | 296.40±23.30* |
| Matched group | 31 | 201.01±30.43 | 235.30±29.24 |
Explanation for table 2 partial content: * P＜0.05.
As can be seen from Table 2, treatment group serum motilin level and has significance (P＜0.05) apparently higher than matched group after treatment.
2.2 untoward reaction
Two groups of patient's untoward reaction are slight.Treatment group times of defecation increases by 2 examples, borborygmus 1 example, and adverse reaction rate is 10.3%; The matched group times of defecation increases by 2 examples, and borborygmus 2 examples are adhered to medication through explanation, the symptom spontaneous remission, and adverse reaction rate is 12.9%.Two groups of difference nonsignificances (P〉0.05).
3 discuss
Functional dyspepsia is the clinical common syndrome of digestive system, cause and onset of disease mechanism is not illustrated so far as yet fully, it is generally acknowledged that influencing the daily life factor that gastrointestinal function brings out the functional dyspepsia symptom generally includes three aspects: the one, and the distress of psychology and spirit; The 2nd, Bad Eating Habit comprise irritable food and Bad Eating Habit; The 3rd, the influence of ambient temperature.Various paathogenic factors finally all are to cause gastrointestinal motility disorder and indigestion symptom occurs.It is uncomfortable and may be to the influence of quality of life that the harm that functional dyspepsia brings to the patient shows mainly that the upper digestive tract symptom causes.Part patient finally causes becoming thin.
Motilin is distributed in small intestinal by gastrointestinal mucosa Mo emiocytosis.Research in recent years points out, the generation of dividing a word with a hyphen at the end of a line property myoelectricity complex wave (MMC) and divide a word with a hyphen at the end of a line and mainly be subjected to the adjusting of enteric nervous system and gut hormone.The generation of MMC is to be released into blood in a large number and to be caused by the motilin that is periodically-varied.So whether detection functionality dyspepsia patient plasma motilin can indirectly observe MMC and lacks, for clinical observation on the therapeutic effect provides important objective basis.
This research in conjunction with observation, is found the moving curative effect that can obviously improve patients with functional dyspepsia of Chinese medicine stomach by clinical efficacy and serum motilin, and also more not husky Billy's treatment group height of serum motilin level after testing, and is proportional with curative effect.As seen the moving side of Chinese medicine stomach can promote digestive tract power by improving serum motilin level, and because many target spots regulating action of Chinese medicine, clinical efficacy is better than urging merely the digestive tract power treatment.
Above-described embodiment only is explanation technical conceive of the present invention and characteristics, and its purpose is to allow the personage who is familiar with this technology can understand content of the present invention and enforcement according to this, can not limit protection scope of the present invention with this.All equivalences that spirit is done according to the present invention change or modify, and all should be encompassed within protection scope of the present invention.
Claims (2)
1. pharmaceutical composition for the treatment of gastrointestinal motility disorder, it is characterized in that: the crude drug by following parts by weight is formed:
Rhizoma Curcumae 10-20 part;
Fructus Amomi 7-15 part;
Semen Arecae 7-15 part;
Radix Aucklandiae 7-15 part;
Radix Et Rhizoma Nardostachyos 7-15 part.
2. the pharmaceutical composition for the treatment of gastrointestinal motility disorder according to claim 1, it is characterized in that: the crude drug by following parts by weight is formed:
Rhizoma Curcumae 12-18 part;
Fructus Amomi 8-12 part;
Semen Arecae 8-12 part;
Radix Aucklandiae 8-12 part;
Radix Et Rhizoma Nardostachyos 8-12 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310226557.2A CN103285326B (en) | 2013-06-08 | 2013-06-08 | Medicine composition for treating gastrointestinal motility disorder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310226557.2A CN103285326B (en) | 2013-06-08 | 2013-06-08 | Medicine composition for treating gastrointestinal motility disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103285326A true CN103285326A (en) | 2013-09-11 |
| CN103285326B CN103285326B (en) | 2014-12-10 |
Family
ID=49087215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310226557.2A Active CN103285326B (en) | 2013-06-08 | 2013-06-08 | Medicine composition for treating gastrointestinal motility disorder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103285326B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497348A (en) * | 2014-11-10 | 2016-04-20 | 李锦梁 | Traditional Chinese medicine for curing dolorosa adiposis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101905001A (en) * | 2009-06-08 | 2010-12-08 | 蔡保君 | Medicament for removing intestinal gas and changing ultrasonic Doppler acoustic impedance |
-
2013
- 2013-06-08 CN CN201310226557.2A patent/CN103285326B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101905001A (en) * | 2009-06-08 | 2010-12-08 | 蔡保君 | Medicament for removing intestinal gas and changing ultrasonic Doppler acoustic impedance |
Non-Patent Citations (1)
| Title |
|---|
| 蒋健: "胃痞证治亚型案例分析与刍议", 《陕西中医》, vol. 31, no. 8, 31 August 2010 (2010-08-31), pages 1088 - 1090 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497348A (en) * | 2014-11-10 | 2016-04-20 | 李锦梁 | Traditional Chinese medicine for curing dolorosa adiposis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103285326B (en) | 2014-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102068707B (en) | Traditional Chinese medicine contrast medium adjuvant used for B ultrasonic and preparation method thereof | |
| CN102284049B (en) | A kind ofly alleviate compound Chinese medicinal preparation of chemicotherapy toxicity and uses thereof | |
| CN102772781B (en) | Traditional Chinese medicine preparation for treating chronic colitis and preparation method thereof | |
| CN106720815A (en) | A kind of stem of noble dendrobium coffee for nursing one's health prostatic disorders and preparation method thereof | |
| CN101450149B (en) | Medicine for treating abdominal postoperative stomach palsy syndrome and preparation method | |
| CN104162129B (en) | A kind of Chinese medicine for treating DGP | |
| CN103285260A (en) | Traditional Chinese medicine composition for treating reflux esophagitis | |
| CN104940374A (en) | Warming-yang and tonifying-qi moxibustion treatment cake for treating deficiency cold of spleen and stomach type epiagstric pain | |
| CN103285326B (en) | Medicine composition for treating gastrointestinal motility disorder | |
| CN104998140B (en) | A kind of Chinese medicine preparation for chronic gastric ulcer | |
| CN100509041C (en) | Stomach-clearing pill | |
| CN106620474B (en) | Stomach-nourishing health-care medicine and preparation method thereof | |
| CN105687729A (en) | Traditional Chinese medicine preparation for treating pancreatitis and preparation method of traditional Chinese medicine preparation for treating pancreatitis | |
| CN104784650A (en) | Pharmaceutical preparation for clinical nursing of gastric ulcer | |
| CN109394885A (en) | A kind of Chinese materia medica preparation of anti-nonalcoholic fatty liver | |
| CN104547872A (en) | Traditional Chinese medicine composition for treating epilepsy | |
| CN104784651B (en) | A kind of method for preparing the pharmaceutical preparation for treating gastric ulcer | |
| CN102416043B (en) | Traditional Chinese medicine for treating spleen deficiency diarrhea of children | |
| CN103028028B (en) | Traditional Chinese medicine agent for treating primary hepatic carcinoma | |
| CN1217688C (en) | Medicine for treating chronic gastritis and preparing process thereof | |
| CN109010770A (en) | A kind of externally used medicine bag that conditioning human body is raw | |
| CN105147944A (en) | Traditional Chinese medicine composition, preparation of traditional Chinese medicine composition and preparation method and application of preparation | |
| CN105125688B (en) | A kind of relieving haperacidity analgesic composition containing milk basic protein and preparation method thereof | |
| CN104288740A (en) | Compound thirst-quenching Weining mixture | |
| CN115317583A (en) | Traditional Chinese medicine composition for postoperative gastric cancer and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |